JPH11507934A - 胃腸障害の予防及び治療のための医薬用及び食餌用処方 - Google Patents
胃腸障害の予防及び治療のための医薬用及び食餌用処方Info
- Publication number
- JPH11507934A JPH11507934A JP9503576A JP50357697A JPH11507934A JP H11507934 A JPH11507934 A JP H11507934A JP 9503576 A JP9503576 A JP 9503576A JP 50357697 A JP50357697 A JP 50357697A JP H11507934 A JPH11507934 A JP H11507934A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- glutamine
- composition according
- bacteria
- bacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims abstract description 5
- 230000002265 prevention Effects 0.000 title claims abstract description 5
- 235000014105 formulated food Nutrition 0.000 title abstract description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 46
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 41
- 241000894006 Bacteria Species 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 31
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 12
- 241000186660 Lactobacillus Species 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 229940039696 lactobacillus Drugs 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 241000194031 Enterococcus faecium Species 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 244000052616 bacterial pathogen Species 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 229930064664 L-arginine Natural products 0.000 claims description 2
- 235000014852 L-arginine Nutrition 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 230000003385 bacteriostatic effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 235000007882 dietary composition Nutrition 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 210000004347 intestinal mucosa Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 16
- 230000002496 gastric effect Effects 0.000 description 11
- 239000002775 capsule Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 244000199866 Lactobacillus casei Species 0.000 description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229940017800 lactobacillus casei Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QPTNELDXWKRIFX-YFKPBYRVSA-N Gly-Gly-Gln Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O QPTNELDXWKRIFX-YFKPBYRVSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000009127 Glutaminase Human genes 0.000 description 1
- 108010073324 Glutaminase Proteins 0.000 description 1
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000037435 normal mutation Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Confectionery (AREA)
- Seasonings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.−少なくとも、1用量当たり106〜1012細胞、好ましくは1用量当たり 108〜1011細胞の範囲の量の腸内良性細菌株、 −1用量当たり0.5〜10g、好ましくは1用量当たり2〜5gの範囲の量 のグルタミン、 を含むことを特徴とする、医薬用又は食餌用組成物。 2.グルタミンが、グルタミン含有ポリペプチドにより置換されている、請求項 1記載の組成物。 3.組成物が、更に、0.5〜10g、好ましくは2〜5gの量のL−アルギニ ンを含むことを特徴とする、請求項1又は2記載の組成物。 4.組成物が、更に、0〜10gの範囲の量のショ糖、ブドウ糖若しくはデンプ ンのような単純若しくは複合炭水化物、又は医薬製剤技術において通常使用され る他の任意の安定剤を含むことを特徴とする、請求項1〜3記載の組成物。 5.組成物が、更に、0.5〜10gの量の動物又は植物由来の抽出物の混合物 を含むことを特徴とする、請求項1又は2記載の組成物。 6.少なくとも1つの成分が、凍結乾燥されている、請求項1〜5記載の組成物 。 7.安定剤が、凍結乾燥の前又は後に加えられる、請求項6記載の組成物。 8.該安定剤が、グルタミン、グルタミン含有ポリペプチド、アミノ酸、アスコ ルビン酸、トレハロース及びデンプンを含む炭水化物から選択される、請求項7 記載の組成物。 9.該細菌が、凍結乾燥される、請求項1〜5記載の組成物。 10.安定化されているか又はされていない、該凍結乾燥された細菌が、 他の成分を含む顆粒と混合される、請求項9記載の組成物。 11.凍結乾燥された細菌が、他の化合物とは別個に包装され、2つの包装が医 薬製剤の用量を構成する、請求項9記載の組成物。 12.該細菌が、乳酸菌である、請求項1記載の組成物。 13.該細菌が、乳酸桿菌である、請求項12記載の組成物。 14.該細菌が、腸粘膜に付着することができる乳酸桿菌である、請求項12記 載の組成物。 15.該乳酸桿菌が、健常人の胃腸管から単離される、請求項13記載の組成物 。 16.該乳酸桿菌が、CNCM I−1390株、CNCM I−1391株、 CNCM I−1392株、CNCM I−1447株、ATCC53103株 の1つに属する、請求項13記載の組成物。 17.該細菌が、病原菌に対して殺菌性又は静菌性の作用を示す、請求項1記載 の組成物。 18.該細菌が、Enterococcus faeciumSF68である、請求項1記載の組成物 。 19.該細菌が、その本来持っている耐性により選択されたか、又は1つ以上の 抗生物質に対して耐性になるように突然変異させられたか若しくは遺伝子操作さ れている、請求項1記載の組成物。 20.胃腸障害の予防及び/又は治療のための医薬用又は食餌用組成物の調製の ための、グルタミン又はグルタミン含有ポリペプチドと組合せた腸内良性細菌の 用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT95MI001359A IT1276783B1 (it) | 1995-06-23 | 1995-06-23 | Formulazioni farmaceutiche e dietetiche per la profilassi e la cura di affezioni gastrointestinali |
IT95A001359 | 1995-06-23 | ||
PCT/EP1996/002650 WO1997000688A1 (en) | 1995-06-23 | 1996-06-19 | Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11507934A true JPH11507934A (ja) | 1999-07-13 |
Family
ID=11371866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9503576A Pending JPH11507934A (ja) | 1995-06-23 | 1996-06-19 | 胃腸障害の予防及び治療のための医薬用及び食餌用処方 |
Country Status (18)
Country | Link |
---|---|
US (1) | US6007808A (ja) |
EP (1) | EP0833644B1 (ja) |
JP (1) | JPH11507934A (ja) |
CN (1) | CN1082373C (ja) |
AT (1) | ATE234623T1 (ja) |
AU (1) | AU707399B2 (ja) |
BR (1) | BR9609413A (ja) |
CA (1) | CA2219739A1 (ja) |
DE (2) | DE833644T1 (ja) |
DK (1) | DK0833644T3 (ja) |
ES (1) | ES2194107T3 (ja) |
HU (1) | HUP9901707A3 (ja) |
IT (1) | IT1276783B1 (ja) |
MX (1) | MX9709238A (ja) |
NO (1) | NO976048L (ja) |
NZ (1) | NZ312121A (ja) |
WO (1) | WO1997000688A1 (ja) |
ZA (1) | ZA965235B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006199708A (ja) * | 2002-03-01 | 2006-08-03 | Nisshin Pharma Inc | 肝疾患治療剤 |
WO2007119502A1 (ja) * | 2006-03-23 | 2007-10-25 | Kyowa Hakko Kogyo Co., Ltd. | 便通改善剤 |
JP2009531448A (ja) * | 2006-03-29 | 2009-09-03 | ネステク ソシエテ アノニム | プロバイオティクスを含有する栄養補助食品 |
JP2012512828A (ja) * | 2008-12-18 | 2012-06-07 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | プロバイオティック製剤 |
US10570366B2 (en) | 2011-12-28 | 2020-02-25 | Yamada Bee Company Inc. | Lactic acid bacterium having IgA production promoting activity, and use thereof |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
US20020035071A1 (en) * | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
US20060116330A1 (en) * | 1997-07-08 | 2006-06-01 | The Iams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
US20040166101A1 (en) * | 1999-09-22 | 2004-08-26 | Bojrab Gregory G. | Enchanced composition for treatment of gastrointestinal disorders and hyperlipidemia |
US6641808B1 (en) * | 1999-09-22 | 2003-11-04 | Lacpro Industries, Llc | Composition for treatment of obesity |
WO2001083700A2 (en) * | 2000-05-03 | 2001-11-08 | University Of Maryland, Baltimore | Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal |
US7112570B2 (en) * | 2000-08-24 | 2006-09-26 | Neuren Pharmaceuticals, Ltd. | GPE analogs |
TWI351278B (en) * | 2002-03-01 | 2011-11-01 | Nisshin Pharma Inc | Agent for preventing and treating of liver disease |
ATE421990T1 (de) * | 2002-07-22 | 2009-02-15 | Meito Sangyo Kk | Zusammensetzung zur förderung der vermehrung von lactobacillus casei subsp. casei |
DK175877B1 (da) * | 2002-11-11 | 2005-05-09 | Pharmalett As | Præparater til anvendelse som terapeutisk middel |
WO2005000034A2 (en) * | 2003-06-23 | 2005-01-06 | Agtech Products, Inc. | Lactic bacteria and its use in direct-fed microbials |
US20050100559A1 (en) * | 2003-11-07 | 2005-05-12 | The Procter & Gamble Company | Stabilized compositions comprising a probiotic |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US8877178B2 (en) * | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
US20050158294A1 (en) * | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US8894991B2 (en) * | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
US20050152884A1 (en) * | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
WO2006130188A1 (en) * | 2005-05-31 | 2006-12-07 | The Iams Company | Feline probiotic bifidobacteria |
DK1880001T3 (da) * | 2005-05-31 | 2011-09-12 | Iams Company | Feline probiotiske lactobacilli |
JP5799299B2 (ja) | 2007-02-01 | 2015-10-21 | ザ・アイムス・カンパニーThe Iams Company | ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法 |
CN101259140B (zh) * | 2007-03-08 | 2012-08-22 | 重庆北碚现代应用药物研究所 | 一种治疗胃炎、胃溃疡及十二指肠溃疡的复方药物及其制备方法 |
CN101273737B (zh) * | 2007-03-28 | 2011-08-24 | 哈尔滨正方科技有限公司 | 一种在常温下保持高活菌数的发酵乳饮料的制备方法 |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US20120087902A1 (en) | 2009-07-20 | 2012-04-12 | Bracco S.P.A. | Therapeutic Use Of Probiotics |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4839281A (en) * | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
US5397803A (en) * | 1985-09-12 | 1995-03-14 | Brigham And Women's Hospital | Use of glutamine to reduce rate of pathogenic microorganism infection |
JPH0367046A (ja) * | 1989-08-05 | 1991-03-22 | Mitsubishi Motors Corp | エンジンの吸入空気量制御装置 |
CN1105544A (zh) * | 1994-09-09 | 1995-07-26 | 扬州大学农学院 | 一种制取活性乳酸菌口服液的方法 |
US5531681A (en) * | 1995-01-13 | 1996-07-02 | Abbott Laboratories | Apparatus for altering composition of nutritional product during enteral tube feeding |
-
1995
- 1995-06-23 IT IT95MI001359A patent/IT1276783B1/it active IP Right Grant
-
1996
- 1996-06-19 WO PCT/EP1996/002650 patent/WO1997000688A1/en active IP Right Grant
- 1996-06-19 DE DE0833644T patent/DE833644T1/de active Pending
- 1996-06-19 AT AT96922842T patent/ATE234623T1/de not_active IP Right Cessation
- 1996-06-19 AU AU63575/96A patent/AU707399B2/en not_active Ceased
- 1996-06-19 JP JP9503576A patent/JPH11507934A/ja active Pending
- 1996-06-19 HU HU9901707A patent/HUP9901707A3/hu unknown
- 1996-06-19 DE DE69626818T patent/DE69626818T2/de not_active Expired - Lifetime
- 1996-06-19 CN CN96194976A patent/CN1082373C/zh not_active Expired - Fee Related
- 1996-06-19 ES ES96922842T patent/ES2194107T3/es not_active Expired - Lifetime
- 1996-06-19 DK DK96922842T patent/DK0833644T3/da active
- 1996-06-19 US US08/973,676 patent/US6007808A/en not_active Expired - Lifetime
- 1996-06-19 NZ NZ312121A patent/NZ312121A/xx unknown
- 1996-06-19 BR BR9609413A patent/BR9609413A/pt not_active Application Discontinuation
- 1996-06-19 CA CA002219739A patent/CA2219739A1/en not_active Abandoned
- 1996-06-19 EP EP96922842A patent/EP0833644B1/en not_active Expired - Lifetime
- 1996-06-19 MX MX9709238A patent/MX9709238A/es not_active IP Right Cessation
- 1996-06-20 ZA ZA965235A patent/ZA965235B/xx unknown
-
1997
- 1997-12-22 NO NO976048A patent/NO976048L/no not_active Application Discontinuation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006199708A (ja) * | 2002-03-01 | 2006-08-03 | Nisshin Pharma Inc | 肝疾患治療剤 |
JP4559380B2 (ja) * | 2002-03-01 | 2010-10-06 | 日清ファルマ株式会社 | 肝疾患治療剤 |
WO2007119502A1 (ja) * | 2006-03-23 | 2007-10-25 | Kyowa Hakko Kogyo Co., Ltd. | 便通改善剤 |
JP2009531448A (ja) * | 2006-03-29 | 2009-09-03 | ネステク ソシエテ アノニム | プロバイオティクスを含有する栄養補助食品 |
JP2012512828A (ja) * | 2008-12-18 | 2012-06-07 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | プロバイオティック製剤 |
US10570366B2 (en) | 2011-12-28 | 2020-02-25 | Yamada Bee Company Inc. | Lactic acid bacterium having IgA production promoting activity, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2219739A1 (en) | 1997-01-09 |
DE833644T1 (de) | 1998-09-03 |
NO976048L (no) | 1998-02-23 |
HUP9901707A3 (en) | 2001-04-28 |
BR9609413A (pt) | 1999-05-18 |
AU707399B2 (en) | 1999-07-08 |
MX9709238A (es) | 1998-03-31 |
US6007808A (en) | 1999-12-28 |
HUP9901707A2 (hu) | 1999-09-28 |
IT1276783B1 (it) | 1997-11-03 |
ES2194107T3 (es) | 2003-11-16 |
NO976048D0 (no) | 1997-12-22 |
EP0833644A1 (en) | 1998-04-08 |
NZ312121A (en) | 1999-03-29 |
WO1997000688A1 (en) | 1997-01-09 |
DE69626818T2 (de) | 2003-11-20 |
CN1188413A (zh) | 1998-07-22 |
AU6357596A (en) | 1997-01-22 |
ATE234623T1 (de) | 2003-04-15 |
DE69626818D1 (de) | 2003-04-24 |
CN1082373C (zh) | 2002-04-10 |
ITMI951359A1 (it) | 1996-12-23 |
EP0833644B1 (en) | 2003-03-19 |
DK0833644T3 (da) | 2003-07-21 |
ZA965235B (en) | 1997-01-09 |
ITMI951359A0 (it) | 1995-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11507934A (ja) | 胃腸障害の予防及び治療のための医薬用及び食餌用処方 | |
KR102203837B1 (ko) | 프로바이오틱 캡슐화용 마이크로입자, 그의 제조 및 이용 | |
US6841181B2 (en) | Encapsulated multifunctional biologically active food component, process for its production and its use | |
EP3328215B1 (en) | Stable dry probiotic compositions for special dietary uses | |
AU750136B2 (en) | Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS | |
US10792313B2 (en) | Stable dry compositions having no or little sugars | |
JP2016052323A (ja) | プロバイオティクスの保存と送達 | |
EP0904784A1 (en) | Probiotic nutritional preparation | |
CA2812909C (en) | Compositions and methods for augmenting kidney function | |
US20210161990A1 (en) | Stable dry probiotic compositions for special dietary uses | |
CA2478991A1 (en) | Compositions and methods for augmenting kidney function | |
KR102685914B1 (ko) | 특수 식이 용도를 위한 안정한 프로바이오틱 건조 조성물 | |
JPH03244367A (ja) | 免疫増強用食品添加剤 | |
NZ742496B2 (en) | Stable dry compositions having no or little sugars |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031222 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040622 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040922 Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040922 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070417 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070713 Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070713 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070827 Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070827 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070815 Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070815 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070921 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070914 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071017 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080414 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080514 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080710 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090609 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090612 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090709 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090721 Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090721 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090807 Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090807 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090819 |